drug design

Acpharis provides computational methods and software for early stage drug discovery. Its services include homology modeling of proteins, high throughput virtual screening of databases, assessment of compounds in partner-selected libraries, and development of non-standard drug design technologies. Its proprietary tools explore target protein druggability, identify and characterize druggable binding sites, and select functional groups for targeted compound libraries. It also offers protein-protein docking software and computational solvent mapping.

binding site characterizationcomputational solvent mappinghigh throughput virtual screeninghomology modelingprotein-protein docking

ARIZ Precision Medicine is a preclinical stage biopharmaceutical company in Davis, California, developing precision ligand targeted siRNA cancer therapies. It combines biological and nanotechnologies to target the genetic and epigenetic drivers of cancer, aiming to destroy cancer cells without harming normal cells. Its proof of principle studies showed selective killing of multiple cancer cell types including breast, colon, lung, and myeloma.

gene and protein altering methodologiesnanotechnology drug deliverypreclinical animal model testing

BioSyntex Laboratories, LLC is a small, woman-owned drug discovery and design company developing nanotechnology-driven pharmaceuticals and hybrid therapeutics that combine biologically derived carriers such as vesicles, exosomes, and peptide ligands with small molecule payloads. Its platform targets neuroinflammation and infectious disease along the gut-brain axis, with delivery routes optimized for oral, intranasal, and vesicle-enabled CNS penetration. The company is advancing multiple drug candidates toward IND-enabling studies and welcomes collaborati

drug discoverynano-medicinepharmaceutical researchtargeted drug delivery

Elion Therapeutics is a clinical-stage biopharmaceutical company in Boston, MA, named for Gertrude Elion. Its mission is to deliver safe and effective therapies to prevent and treat infections in highly vulnerable people, particularly those with cancer and transplant care. The company is backed by $82M in Series B financing from Deerfield, AMRAF, and UI Ventures, and its leadership team has shaped nearly every antifungal on the market today.

clinical-stage biopharmaceutical researchclinical studies